Obesity‐related non‐communicable diseases are global health issues. More than 50% of men and women are overweight or obese in the UK, which is associated with increased risk of cardiovascular disease (CVD) among other non‐communicable diseases. Early detection of the risk of CVD development within high‐risk groups is urgently needed to reduce the burden of this disease. Several mechanisms underlie...
YH4808, a K+‐competitive acid blocker, is under clinical development for the treatment of acid‐related disorders, such as gastroesophageal reflux disease.
To determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH4808, compared to placebo and esomeprazole.
This double‐blind, randomised, placebo‐ and active comparator (esomeprazole)‐controlled...
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.